Sai Parenterals Acquires 60% Stake in Prathyak Laboratories for Rs 15 Crore

Acquisition Price: Rs 15 crore | Target: 60% stake in Prathyak Laboratories

Reader Takeaway: Acquisition replaces greenfield project, securing ready-to-use R&D infrastructure and a specialized team for complex injectables.

What just happened

Sai Parenterals has acquired a 60% equity stake in Prathyak Laboratories Private Limited for Rs 15 crore. The transaction is funded via unutilized proceeds from the company's IPO. Following the deal, the target company has been renamed Sai Prathyak Laboratories Private Limited. The company has also secured a Right of First Refusal (ROFR) for the remaining 40% stake, which it plans to acquire via internal accruals at current valuations.

Why this matters

The acquisition grants Sai Parenterals immediate control over an established R&D centre located in Genome Valley, Hyderabad. Rather than building a new facility, the company has secured a readymade platform including 28 research scientists and a portfolio of 150 SKUs across 86 molecules. This is designed to support the company’s expansion into lyophilised, liposomal, and oncology injectables for regulated international markets.

Operational Impact

This move strengthens the company's internal value chain. The R&D centre is expected to facilitate product development for existing supply agreements in Australia and New Zealand. Management, led by Chairman Anil Kumar Karusala, noted that this strategy eliminates construction-related delays and allows the company to integrate complex injectable capabilities directly under its own brand.

Risks to watch

Investors should monitor the integration of the acquired R&D team and the technical success of the existing product pipeline. The ability to translate these 86 molecules into commercial-ready products within the projected timeframes will be critical for long-term margin stability and growth.

What to track next

Watch for updates on the conversion of the current 60% holding to full ownership and the progress of product filings resulting from the Hyderabad R&D facility. Market participants will be looking for improved output from the injectable segment in upcoming quarterly results.